New combo attack on hard-to-treat prostate cancer shows promise
NCT ID NCT03503344
First seen Jan 27, 2026 · Last updated Jun 19, 2026 · Updated 26 times
Summary
This study tested whether adding a precise, high-dose radiation treatment (SBRT) to the hormone therapy apalutamide helps control prostate cancer that has stopped responding to standard hormone therapy and spread to a few spots. Twenty-six men with this type of cancer took part. The main goal was to see if the combination could make PSA levels undetectable after 18 months. The approach aims to delay the cancer's progression while keeping side effects manageable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of California, San Francisco
San Francisco, California, 94115, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.